4th Quarter - Report

W STRATEGIES, LLC for ALEXION PHARMACEUTICALS

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

H.R.5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models. Educated staff about access to therapies for rare diseases in Medicaid. March 2016 CMS proposed rule implementing a new Part B drug payment model.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 5122 (114th)

Health Issues HCR

Education about the value of innovative new medicines. H.R. 34: 21st Century Cures Act as it relates to S. 1878: To extend the pediatric priority review voucher program. S. 3056: CREATES Act of 2016.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 1878 (114th), H.R. 34 (114th), S. 3056 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.